Home
EDIT
EDIT News

Latest Editas Medicine Inc. (EDIT) News on October 23, 2025

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

GlobeNewswire

14 days ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Scientific Equipment Goes to Auction in Tiger Group and EquipNet Sale on Oct. 16

PR Newswire

15 days ago

Scientific Equipment Goes to Auction in Tiger Group and EquipNet Sale on Oct. 16

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

GlobeNewswire

17 days ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

MT Newswires

17 days ago

KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Motley Fool

4 months ago

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

2 Beaten-Down Stocks to Avoid

Motley Fool

4 months ago

2 Beaten-Down Stocks to Avoid

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Motley Fool

4 months ago

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

GlobeNewswire

4 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

Zacks

4 months ago

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

1 Stock Down 97% That Could Double, According to Wall Street

Motley Fool

5 months ago

1 Stock Down 97% That Could Double, According to Wall Street

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Pharma Voice

5 months ago

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

GlobeNewswire

5 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

5 months ago

Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire

5 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

Zacks

5 months ago

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y

Zacks

5 months ago

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire

5 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Zacks

5 months ago

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

5 months ago

Editas: Q1 Earnings Snapshot

Editas Medicine Announces First Quarter 2025 Results and Business Updates

GlobeNewswire

5 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

GlobeNewswire

5 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

5 months ago

Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

GlobeNewswire

6 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire

6 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

MT Newswires

6 months ago

HC Wainwright Initiates Coverage on Editas Medicine With Buy Rating, $3 Price Target

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year

Simply Wall St.

6 months ago

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

Zacks

7 months ago

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

AstraZeneca deepens China investment; Editas loses CFO to Dyne

BioPharma Dive

7 months ago

AstraZeneca deepens China investment; Editas loses CFO to Dyne

MT Newswires

7 months ago

Dyne Therapeutics Names Erick Lucera as CFO

Editas Medicine Announces Chief Financial Officer Transition

GlobeNewswire

7 months ago

Editas Medicine Announces Chief Financial Officer Transition

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

Simply Wall St.

7 months ago

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Zacks

8 months ago

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

Zacks

8 months ago

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

Associated Press Finance

8 months ago

Editas: Q4 Earnings Snapshot

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

GlobeNewswire

8 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

GlobeNewswire

8 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

8 months ago

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

TipRanks

9 months ago

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Zacks

9 months ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

GlobeNewswire

9 months ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Zacks

9 months ago

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

Insider Monkey

10 months ago

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Zacks

10 months ago

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

MT Newswires

10 months ago

JPMorgan Downgrades Editas Medicine to Underweight From Neutral

Editas Medicine price target lowered to $8 from $10 at Baird

TipRanks

10 months ago

Editas Medicine price target lowered to $8 from $10 at Baird

Investing.com

10 months ago

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts

GuruFocus.com

10 months ago

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts

MT Newswires

10 months ago

JonesTrading Downgrades Editas Medicine to Hold From Buy

MT Newswires

10 months ago

Stifel Downgrades Editas Medicine Hold From Buy, Adjusts Price Target to 3 From $11

MT Newswires

10 months ago

Truist Securities Downgrades Editas Medicine Hold From Buy

MT Newswires

10 months ago

RBC Cuts Price Target on Editas Medicine to $4 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires

10 months ago

Truist Downgrades Editas Medicine to Hold From Buy, Removes $8 Price Target

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Benzinga

10 months ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

MT Newswires

10 months ago

Editas Medicine Focuses on In Vivo Gene-Editing Medicines, Ends Reni-Cel Development to Cut Costs

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

GlobeNewswire

10 months ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas to lay off staff after search for sickle cell partner comes up empty

BioPharma Dive

10 months ago

Editas to lay off staff after search for sickle cell partner comes up empty

MT Newswires

10 months ago

Wells Fargo Downgrades Editas Medicine to Equal Weight From Overweight, Cuts Price Target to $4 From $7

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

Zacks

10 months ago

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

MT Newswires

10 months ago

Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire

10 months ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Zacks

a year ago

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Editas Medicine downgraded to Underperform from Buy at BofA

TipRanks

a year ago

Editas Medicine downgraded to Underperform from Buy at BofA

MT Newswires

a year ago

BofA Securities Downgrades Editas Medicine to Underperform

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Editas Medicine to Participate in Upcoming Investor Conferences

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%

Simply Wall St.

a year ago

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty

GuruFocus.com

a year ago

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

Zacks

a year ago

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

a year ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations

MT Newswires

a year ago

Raymond James Downgrades Editas Medicine to Market Perform From Outperform

MT Newswires

a year ago

Truist Securities Adjusts Editas Medicine's Price Target to $8 From $12, Keeps Buy Rating

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Zacks

a year ago

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

a year ago

Editas: Q3 Earnings Snapshot

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

GlobeNewswire

a year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?

Insider Monkey

a year ago

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

Zacks

a year ago

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

Zacks

a year ago

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Zacks

a year ago

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

MT Newswires

a year ago

Chardan Cuts Price Target on Editas Medicine to $12 From $20, Keeps Buy Rating

Editas and Genevant team up to develop gene editing therapies

Pharmaceutical Technology

a year ago

Editas and Genevant team up to develop gene editing therapies

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

Zacks

a year ago

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

MT Newswires

a year ago

Editas Medicine Achieves Proof of Concept for In Vivo Gene Editing of Hematopoietic Stem Cells in Humanized Mice

Editas, changing course again, looks to partner lead CRISPR therapy

BioPharma Dive

a year ago

Editas, changing course again, looks to partner lead CRISPR therapy

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

GlobeNewswire

a year ago

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

MT Newswires

a year ago

Editas Medicine, Genevant Partner to Develop mRNA-LNP Gene Editing Therapeutics

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

GlobeNewswire

a year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

GlobeNewswire

a year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings

GuruFocus.com

a year ago

State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings

Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company

Simply Wall St.

a year ago

Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company

Editas Medicine Secures $57M Deal for Gene-Editing Technology

TipRanks

a year ago

Editas Medicine Secures $57M Deal for Gene-Editing Technology

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Pharmaceutical Technology

a year ago

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

MT Newswires

a year ago

National Bank on DRI Healthcare's Casgevy Stream Acquisition

Editas trades Vertex fees for upfront cash in DRI deal

BioPharma Dive

a year ago

Editas trades Vertex fees for upfront cash in DRI deal

MT Newswires

a year ago

DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million

MT Newswires

a year ago

Editas Medicine Sells Future License Fees for Gene-Editing Technology for $57 Million

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

GlobeNewswire

a year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

MT Newswires

a year ago

JonesTrading Initiates Editas Medicine at Buy With $13 Price Target

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?

Zacks

a year ago

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?

Share on Social Networks: